Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06591377

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Led by Kafrelsheikh University · Updated on 2025-09-18

900

Participants Needed

2

Research Sites

59 weeks

Total Duration

On this page

Sponsors

K

Kafrelsheikh University

Lead Sponsor

E

El-Sahel Teaching Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

CONDITIONS

Official Title

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • First-ever large-vessel minor ischemic stroke or transient ischemic attack (TIA)
  • Received antiplatelet treatment within 24 hours of stroke onset
  • Not eligible for rt-PA treatment
  • Both genders included
Not Eligible

You will not qualify if you...

  • No follow-up for 90 days after enrollment
  • NIHSS score less than 5 or rapidly resolving symptoms before imaging
  • History of persistent or recurrent central nervous system diseases such as epilepsy, meningioma, multiple sclerosis, or head trauma with lasting neurological deficits
  • Clinical seizures at stroke onset
  • Major organ failure, active cancer, or acute myocardial infarction within past 6 weeks
  • Use of warfarin, regular ticagrelor within the week before admission, or chemotherapy within the past year
  • Active peptic ulcers, recent gastrointestinal surgery, or bleeding within the last year
  • Major surgery within the last three months
  • Known allergy to study drugs
  • INR greater than 1.4 or PT greater than 18
  • Blood glucose less than 50 or greater than 400 mg/dL
  • Blood pressure less than 90/60 or greater than 185/110 mmHg on admission
  • Platelet count less than 100,000
  • Pregnant or lactating patients
  • Stroke due to venous thrombosis, cardiac arrest, or severe low blood pressure
  • Contraindications to study drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

El-sahel teaching hospital

Cairo, Egypt, 22514

Actively Recruiting

2

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt, 33511

Actively Recruiting

Loading map...

Research Team

M

mohamed G. Zeinhom, MD

CONTACT

S

sherihan R. ahmed, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here